The first patient has been dosed in a Phase 2 trial of BGE-102, an oral pill built on human aging research, aimed at preserving vision.

Link as first comment.

#longevity #geroscience #BGE102 #aging #vision

The company expands its Phase 1 trial after early signals show BGE-102’s potential to address inflammation beyond the reach of GLP-1 drugs.

longevity.technology/news/bioage-...

#longevity #BioAge #BGE102 #biotech #healthspan